search
Back to results

Incremental Value of Point of Care H-FABP Testing in Primary Care Patients Suspected of Acute Coronary Syndrome (RAPIDA)

Primary Purpose

Acute Coronary Syndrome, Angina Pectoris, Unstable, Angina Pectoris, Stable

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
heart type fatty acid binding protein testing
Sponsored by
Maastricht University Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Acute Coronary Syndrome

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • new-onset chest complaint, considered to be of possible cardiac origin by the general practitioner
  • In case of death of identified cause patients are included as well.

Exclusion Criteria:

  • all attention has to be on acute support for the patient
  • symptoms are present for more than 24 hours
  • oral informed consent is not given during presentation
  • written informed consent is refused afterwards
  • a traumatic cause is present
  • complaints are presented that can be regarded as a recurrence of earlier complaints with clear diagnosis in the past
  • death of unidentified cause.

Sites / Locations

  • ACHG
  • BeRoEmD
  • SGE
  • HOZL
  • ZIO
  • Omnes
  • Cohesie

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

patients

Arm Description

heart type fatty acid binding protein testing

Outcomes

Primary Outcome Measures

diagnostic value of point of care heart type fatty acid binding protein testing for acute myocardial infection, alone as well as in combination with a clinical diagnostic algorithm
Sensitivity, specificity, positive and negative predictive value of point of care heart type fatty acid binding protein testing for acute myocardial infection, alone as well as in combination with a clinical diagnostic algorithm. To determine influence of sex, age, duration of the complaints, and kidney function on clinical performance of heart type fatty acid binding protein testing, subgroup analysis within our study population will be performed

Secondary Outcome Measures

cost-effectiveness
An economic evaluation by means of an incremental cost-effectiveness ratio will be performed. This evaluation will be performed by determination of the ratio between the difference in costs and the difference in benefits between the two strategies that are observed in this study, being the usual reference policy of the general practitioner and the reference policy that could be created when a determined algorithm combined with point of care heart type fatty acid binding protein testing would be used.
definition of an algorithm towards diagnosing acute coronary syndrome and unstable angina
Predictive value of a diagnostic algorithm towards diagnosing acute coronary syndrome and unstable angina is determined, since unstable angina is a condition without rise in biomarkers, but should not be missed by a general practitioner assessing thoracic complaints

Full Information

First Posted
April 4, 2013
Last Updated
April 10, 2017
Sponsor
Maastricht University Medical Center
Collaborators
FABPulous B.V.
search

1. Study Identification

Unique Protocol Identification Number
NCT01826994
Brief Title
Incremental Value of Point of Care H-FABP Testing in Primary Care Patients Suspected of Acute Coronary Syndrome
Acronym
RAPIDA
Official Title
Incremental Value of Heart-type Fatty Acid-Binding Protein (H-FABP) in Evaluating Patients Presenting With Symptoms Possibly Matching Acute Coronary Syndrome in Primary Care
Study Type
Interventional

2. Study Status

Record Verification Date
April 2017
Overall Recruitment Status
Completed
Study Start Date
September 2013 (undefined)
Primary Completion Date
December 2016 (Actual)
Study Completion Date
December 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Maastricht University Medical Center
Collaborators
FABPulous B.V.

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Rationale: Thoracic complaints, possibly due to a cardiac ischemic cause are a diagnostic challenge in general practice. When an underlying ischemic cardiac condition (AMI (acute myocardial infarction), UAP (unstable angina pectoris)) is considered, referral from general practitioner (GP) to a cardiologist has to take place. However, cardiac analysis in 80% of referred patients is negative. To optimize referral decisions of GPs, new and fast diagnostics are needed. Objective: To assess the incremental diagnostic value for AMI of a novel rapid PoC H-FABP-test in addition to history taking and physical examination in patients presenting in daily general practice with possible AMI. In addition the cost-effectiveness of the test will be evaluated. Study design: Delayed type cross-sectional diagnostic study. Study population: Patients presenting to the GP with any new-onset chest complaint, at time of presentation not lasting for more than 24 hours, that is considered to be of possible cardiac origin by the GP. Intervention: Point of care Heart Type Fatty Acid Binding Protein test (PoC H-FABP-test), added to usual care. PoC H-FABP-testing, by qualitatively measuring H-FABP in one single drop of blood obtained by finger prick, is added to normal procedures of consultation and referral decision by the GP. Main study parameters / endpoints: Sensitivity, specificity, positive and negative predictive value of point of care H-FABP-testing for AMI, alone as well as part of a clinical diagnostic algorithm, in patients with thoracic complaints in general practice. All outcome measures, based on using an algorithm and/or point of care H-FABP-testing, will be compared to regular diagnostic assessment by the GP without using an algorithm and/or point of care H-FABP-testing. Therefore, incremental value of H-FABP-testing and/or a diagnostic algorithm is measured. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Individual participants will experience low risk, since study participation comprehends regular care except for an extra finger prick and possibly collection of one extra venous blood sample. For this low amount of disadvantage, the participant will experience no advantage either. However, results of the study will possibly be useful for similar patients in future.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Coronary Syndrome, Angina Pectoris, Unstable, Angina Pectoris, Stable, Thoracic Diseases

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
303 (Actual)

8. Arms, Groups, and Interventions

Arm Title
patients
Arm Type
Other
Arm Description
heart type fatty acid binding protein testing
Intervention Type
Device
Intervention Name(s)
heart type fatty acid binding protein testing
Primary Outcome Measure Information:
Title
diagnostic value of point of care heart type fatty acid binding protein testing for acute myocardial infection, alone as well as in combination with a clinical diagnostic algorithm
Description
Sensitivity, specificity, positive and negative predictive value of point of care heart type fatty acid binding protein testing for acute myocardial infection, alone as well as in combination with a clinical diagnostic algorithm. To determine influence of sex, age, duration of the complaints, and kidney function on clinical performance of heart type fatty acid binding protein testing, subgroup analysis within our study population will be performed
Time Frame
one and a half year
Secondary Outcome Measure Information:
Title
cost-effectiveness
Description
An economic evaluation by means of an incremental cost-effectiveness ratio will be performed. This evaluation will be performed by determination of the ratio between the difference in costs and the difference in benefits between the two strategies that are observed in this study, being the usual reference policy of the general practitioner and the reference policy that could be created when a determined algorithm combined with point of care heart type fatty acid binding protein testing would be used.
Time Frame
one and a half year
Title
definition of an algorithm towards diagnosing acute coronary syndrome and unstable angina
Description
Predictive value of a diagnostic algorithm towards diagnosing acute coronary syndrome and unstable angina is determined, since unstable angina is a condition without rise in biomarkers, but should not be missed by a general practitioner assessing thoracic complaints
Time Frame
one and a half year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: new-onset chest complaint, considered to be of possible cardiac origin by the general practitioner In case of death of identified cause patients are included as well. Exclusion Criteria: all attention has to be on acute support for the patient symptoms are present for more than 24 hours oral informed consent is not given during presentation written informed consent is refused afterwards a traumatic cause is present complaints are presented that can be regarded as a recurrence of earlier complaints with clear diagnosis in the past death of unidentified cause.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Geert Jan Dinant, professor
Organizational Affiliation
Maastricht University
Official's Role
Study Chair
Facility Information:
Facility Name
ACHG
City
Leuven
State/Province
Vlaams Brabant
ZIP/Postal Code
B-3000
Country
Belgium
Facility Name
BeRoEmD
City
Den Bosch
State/Province
Brabant
ZIP/Postal Code
5258KG
Country
Netherlands
Facility Name
SGE
City
Eindhoven
State/Province
Brabant
ZIP/Postal Code
5622AB
Country
Netherlands
Facility Name
HOZL
City
Heerlen
State/Province
Limburg
ZIP/Postal Code
6411TE
Country
Netherlands
Facility Name
ZIO
City
Maastricht
State/Province
Limburg
ZIP/Postal Code
6221 BG
Country
Netherlands
Facility Name
Omnes
City
Sittard
State/Province
Limburg
ZIP/Postal Code
6135 LH
Country
Netherlands
Facility Name
Cohesie
City
Venlo
State/Province
Limburg
ZIP/Postal Code
5912 PN
Country
Netherlands

12. IPD Sharing Statement

Citations:
PubMed Identifier
25738970
Citation
Willemsen RT, Buntinx F, Winkens B, Glatz JF, Dinant GJ; 'RAPIDA'-study team. The value of signs, symptoms and plasma heart-type fatty acid-binding protein (H-FABP) in evaluating patients presenting with symptoms possibly matching acute coronary syndrome: background and methods of a diagnostic study in primary care. BMC Fam Pract. 2014 Dec 12;15:203. doi: 10.1186/s12875-014-0203-8.
Results Reference
derived

Learn more about this trial

Incremental Value of Point of Care H-FABP Testing in Primary Care Patients Suspected of Acute Coronary Syndrome

We'll reach out to this number within 24 hrs